Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 7.
doi: 10.1111/cen.70048. Online ahead of print.

Bone Health in Patients With Adrenal Adenomas and Hypercortisolism: A Multicenter Cross-Sectional Study

Prerna Dogra  1   2 , Lana Šambula  3 , Jasmine Saini  1   4 , Matthew T Drake  1   5 , Shobana Athimulam  6 , Stylianos Tsagarakis  7 , Dimitra A Vassiliadi  7 , Vasiliki Antonopoulou  7 , Rohit Nathani  1   8 , Catherine D Zhang  1   9 , Natalia Genere  10 , Urszula Ambroziak  11 , Joanna Hubska  11   12 , Raul G Garcia  1   13 , Mohamed Bassiony  1 , Bahaa H Salama  1 , Elizabeth J Atkinson  14 , Vanessa Fell  1 , Darko Kastelan  15 , Joseph J Larson  14 , Irina Bancos  1
Affiliations

Bone Health in Patients With Adrenal Adenomas and Hypercortisolism: A Multicenter Cross-Sectional Study

Prerna Dogra et al. Clin Endocrinol (Oxf). .

Abstract

Objective: Data on bone health in patients with mild autonomous cortisol secretion (MACS) are limited and heterogenous. We sought to assess the prevalence of osteoporosis and symptomatic fragility fractures in patients with adrenal adenomas and hypercortisolism, and explore associations with the degree of cortisol excess and frailty.

Design: This multicenter cross -sectional study involved prospective enrollment of adults with nonfunctioning adrenal adenomas (NFA), MACS, Cushing syndrome (CS) and referent subjects without adrenal disorders during the study period (January 2019-September 2022). All participants completed a bone health questionnaire at enrollment and had dual-energy X-ray absorptiometry bone mineral density assessment within 12-months. Final analyses were adjusted for age, sex, body mass index, smoking status, alcohol use.

Results: Participants included 117 with NFA (median age 62 years, 80% women), 191 with MACS (median age 63 years, 74% women), 62 with CS (median age 50 years, 92% women), and 101 referent subjects (median age 59 years, 47% women). Both patients with CS (OR: 3.0, 95% CI: 1.1-8.3) and MACS (OR: 2.2, 95% CI: 1.9-4.9) had a higher prevalence of osteoporosis when compared to referents. Among patients with MACS, only those with post 1-mg dexamethasone suppression test (post-1mg-DST) cortisol > 83 nmol/L had a higher prevalence of osteoporosis when compared to referents (OR: 3.2, 95% CI: 1.4-7.5) and NFA (OR: 2.2, 95% CI: 1.1-4.4). For clinical fragility fractures, only patients with CS showed an increased prevalence when compared to referents (OR: 6.1, 95% CI: 1.7-26.4) and NFA (OR: 3.8, 95% CI: 1.3-11.2). Prevalence of clinical fragility fractures was similar to referents in patients with MACS (OR: 1.8, 95% CI: 0.6-6.9) and NFA (OR: 1.5, 95% CI: 0.4-6.1), and was not associated with post-1mg-DST cortisol or frailty in the MACS and NFA groups.

Conclusion: Patients with CS, and those with MACS and post-1mg-DST cortisol > 83 nmol/L, exhibited a higher burden of osteoporosis. However, only CS was associated with an elevated risk of symptomatic fragility fractures.

Keywords: adrenal adenoma; dexamethasone suppression test; fragility fracture; mild autonomous cortisol secretion; osteoporosis.

PubMed Disclaimer

References

    1. A. Klibanski, L. Adams‐Campbell, T. Bassford, et al., “NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis Prevention, Diagnosis, and Therapy,” JAMA: Journal of the American Medical Association 285, no. 6 (2001): 785–795, https://doi.org/10.1001/jama.285.6.785.
    1. P. R. Ebeling, H. H. Nguyen, J. Aleksova, A. J. Vincent, P. Wong, and F. Milat, “Secondary Osteoporosis,” Endocrine Reviews 43, no. 2 (March 2022): 240–313, https://doi.org/10.1210/endrev/bnab028.
    1. G. Reimondo, E. Castellano, M. Grosso, et al., “Adrenal Incidentalomas Are Tied to Increased Risk of Diabetes: Findings From a Prospective Study,” Journal of Clinical Endocrinology and Metabolism 105, no. 4 (April 2020): e973–e981, https://doi.org/10.1210/clinem/dgz284.
    1. M. Fassnacht, S. Tsagarakis, M. Terzolo, et al., “European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenal Incidentalomas, in Collaboration With the European Network for the Study of Adrenal Tumors,” European Journal of Endocrinology 189, no. 1 (July 2023): G1–G42, https://doi.org/10.1093/ejendo/lvad066.
    1. I. C. M. Pelsma, M. Fassnacht, S. Tsagarakis, et al., “Comorbidities in Mild Autonomous Cortisol Secretion and the Effect of Treatment: Systematic Review and Meta‐Analysis,” European Journal of Endocrinology 189, no. 4 (October 2023): S88–S101, https://doi.org/10.1093/ejendo/lvad134.

LinkOut - more resources